Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma

Objective Ovarian clear cell carcinoma (OCCC) is often resistant to conventional, standard chemotherapy using cytotoxic drugs. OCCC harbors a unique genomic feature of frequent (approximately 50%) ARID1A deficiency. The present study was performed to investigate standard chemotherapeutic options suitable for ARID1A-deficient OCCC patients. Methods Drugs with selective toxicity to ARID1A-deficient OCCC cells were identified among six cytotoxic...